Antibodies, Assay Kits, cDNA, Cell-to-cell contact with hepatitis C virus-infected cells reduces functional capacity of natural killer cells, Chronic shift-lag alters the circadian clock of NK cells and promotes lung cancer growth in rats, Clia Kits, Culture Cells, Delineation and Modulation of the Natural Killer Cell Transcriptome in Rhesus Macaques During ZIKV and SIV Infections., Devices, DNA Templates, DNA Testing, Elisa Kits, Enzymes, Equipments, Functions of natural killer cells, Gels, General, Healthy Neonates Possess a CD56-Negative NK Cell Population with Reduced Anti-Viral Activity, Human mesenchymal stem cells modulate allogeneic immune cell responses, Human NK cells kill resting but not activated microglia via NKG2D- and NKp46-mediated recognition, Isotypes, Medium & Serums, Overview of Strategies to Improve Therapy against Tumors Using Natural Killer Cell., Panel, Particles, Pcr Kits, Peptides, Reagents, Ria Kits, RNA, TRP Channels as Interior Designers: Remodeling the Endolysosomal Compartment in Natural Killer Cells., Vector & Virus

Antigens of Mycobacterium tuberculosis Stimulate CXCR6+ Natural Killer Cells

Natural killer (NK) cells take part in immunity in opposition to a number of pathogens by exerting cytotoxic and cytokine-production actions. Some NK cell subsets additionally mediate recall responses that resemble reminiscence of adaptive lymphocytes in opposition to antigenic and non-antigenic stimuli. The C-X-C motif chemokine receptor 6 (CXCR6) is essential for the event and upkeep of memory-like responses in murine NK cells. In people, a number of subsets of tissue-resident and circulating NK cells with totally different purposeful properties specific CXCR6. However, the function of CXCR6+ NK cells in immunity in opposition to related human pathogens is unknown. Here, we addressed whether or not murine and human CXCR6+ NK cells reply to antigens of Mycobacterium tuberculosis (Mtb). For this function, we evaluated the immunophenotype of hepatic and splenic CXCR6+ NK cells in mice uncovered to a cell-wall (CW) extract of Mtb pressure H37Rv. Also, we characterised the expression of CXCR6 in peripheral NK cells from energetic pulmonary tuberculosis (ATB) sufferers, people with latent TB an infection (LTBI), and wholesome volunteer donors (HD). Furthermore, we evaluated the responses of CXCR6+ NK cells from HD, LTBI, and ATB topics to the in vitro publicity to CW preparations of Mtb H37Rv and Mtb HN878.

Our outcomes confirmed that murine hepatic CXCR6+ NK cells broaden in vivo after consecutive administrations of Mtb H37Rv CW to mice. Remarkably, pooled hepatic and splenic, however not remoted splenic NK cells from handled mice, improve their cytokine manufacturing capability after an in vitro re-challenge with H37Rv CW. In people, CXCR6+ NK cells had been barely detected within the peripheral blood, though barely significative increments within the proportion of CXCR6+, CXCR6+CD49a-, CXCR6+CD49a+, and CXCR6+CD69+ NK cells had been noticed in ATB sufferers as in comparison with HD and LTBI people. In distinction, the growth of CXCR6+CD49a- and CXCR6+CD69+ NK cells in response to the in vitro stimulation with Mtb H37Rv was increased in LTBI people than in ATB sufferers. Finally, we discovered that Mtb HN878 CW generates IFN-γ-producing CXCR6+CD49a+ NK cells. Our outcomes exhibit that antigens of each laboratory-adapted and scientific Mtb strains are stimulating elements for murine and human CXCR6+ NK cells. Future research evaluating the function of CXCR6+ NK cells throughout TB are warranted.

Haploidentical transplantation in sufferers with a number of myeloma making use of pure killer cell alloreactive donors

Disease relapse is a vital downside after allogeneic stem cell transplantations in a number of myeloma (MM). To check the speculation that pure killer (NK) cell alloreactivity within the setting of a haploidentical stem cell transplantation (haploSCT) can cut back the chance of myeloma relapse, we carried out a small potential part 2 examine during which we transplanted poor-risk MM sufferers utilizing a killer cell immunoglobulin-like receptor (KIR)-ligand mismatched haploidentical donor. Patients obtained bone marrow grafts after reduced-intensity conditioning, with post-transplantation cyclophosphamide (PTCY) graft-versus-host-disease (GVHD) prophylaxis. The major endpoint was 1.5-year progression-free survival (PFS); stopping guidelines had been put in in case interim outcomes made a profit of 50% PFS at 1.5 years unlikely.

After inclusion of 12 sufferers, of which 9 had been evaluable for the first endpoint, all sufferers relapsed inside a median time of 90 days. All besides 1 affected person confirmed engraftment, with a median time to neutrophil restoration of 18 (12-30) days. The examine was prematurely terminated primarily based on the predefined stopping guidelines after the inclusion of 12 sufferers. With this small examine, we present that in chemo-resistant myeloma sufferers, NK cell KIR-mismatch just isn’t superior to traditional alloSCT. This technique, nevertheless, can function a platform for brand spanking new remedy ideas.Clinical Trial Registry

Irradiated Tumor Fibroblasts Avoid Immune Recognition and Retain Immunosuppressive Functions Over Natural Killer Cells

Primary Gastrointestinal Involvement in a Case of Extranodal-Extranasal Natural Killer T Cell Lymphoma

Extra-nasal varieties of Extra-nodal pure killer cell lymphoma (ENKL) have been identified with poorer prognoses than nasal kind with the worst responses to remedy. The present work introduces a case of ENKL with GI involvement with no nasal manifestations. We report a 56-year male farmer with fever, productive cough, dyspnea, anorexia, vomiting and chill along with malaise and cachexia of three months period referred to a hospital with acute stomach ache, and was identified as peritonitis because of perforated terminal ileum ulcer earlier than experiencing surgical procedure as a case of acute stomach. The pathologic examine of the related biopsy confirmed “ulceration and necrosis with dense fibrinoleukocytic exudation and granulation tissue formation. CT scan decided a bilateral mass like haziness which was extra more likely to be metastatic.

The evaluation of the earlier pathologic specimens raised Natural Killer/T cell Lymphoma (NKTL), the explanation for which we centered on the affected person’s sinuses and nasal space in addition to nasopharynx. There was no discovering in examination and endoscopy of sinuses. Pathology additionally discovered malignant excessive grade non-Hodgkin T cell lymphoma in specimens obtained from debridement of ulcer at terminal ileum. It additionally confirmed that almost all of the tumor cells had been optimistic for CD3, CD56, CD8, and LCA however damaging for CD19, CD20 and AE1/AE3.

Positive reactions for CD30 had been proven by some cells. CD56, CD3, and CD8 had been expressed by neoplastic cells and CD30 had been optimistic in few cells. Proliferative exercise (Ki67 index) was excessive (60-70%). This was the primary base to diagnose an extra-nodal extra-nasal NK/T cell lymphoma. In conclusion, Intestinal modifications at center age, particularly in males with nonspecific scientific manifestations is very suggested to be studied pathologically and genetically for T cell varieties like CD30 optimistic T cells that are normally engaged in ENKTL.

Antibodies, Assay Kits, cDNA, Cell-to-cell contact with hepatitis C virus-infected cells reduces functional capacity of natural killer cells, Chronic shift-lag alters the circadian clock of NK cells and promotes lung cancer growth in rats, Clia Kits, Culture Cells, Delineation and Modulation of the Natural Killer Cell Transcriptome in Rhesus Macaques During ZIKV and SIV Infections., Devices, DNA Templates, DNA Testing, Elisa Kits, Enzymes, Equipments, Functions of natural killer cells, Gels, General, Healthy Neonates Possess a CD56-Negative NK Cell Population with Reduced Anti-Viral Activity, Human mesenchymal stem cells modulate allogeneic immune cell responses, Human NK cells kill resting but not activated microglia via NKG2D- and NKp46-mediated recognition, Isotypes, Medium & Serums, Overview of Strategies to Improve Therapy against Tumors Using Natural Killer Cell., Panel, Particles, Pcr Kits, Peptides, Reagents, Ria Kits, RNA, TRP Channels as Interior Designers: Remodeling the Endolysosomal Compartment in Natural Killer Cells., Vector & Virus

Irradiated Tumor Fibroblasts Avoid Immune Recognition and Retain Immunosuppressive Functions Over Natural Killer Cells

Recent research have demonstrated that radiotherapy is ready to induce anti-tumor immune responses along with mediating direct cytotoxic results. Cancer-associated fibroblasts (CAFs) are central constituents of the tumor stroma and take part actively in tumor immunoregulation. However, the capability of CAFs to affect immune responses within the context of radiotherapy continues to be poorly understood. This research was undertaken to find out whether or not ionizing radiation alters the CAF-mediated immunoregulatory results on pure killer (NK) cells. CAFs had been remoted from freshly resected non-small cell lung most cancers tissues, whereas NK cells had been ready from peripheral blood of wholesome donors.

Functional assays to review NK cell immune activation included proliferation charges, expression of cell floor markers, secretion of immunomodulators, cytotoxic assays, in addition to manufacturing of intracellular activation markers reminiscent of perforin and granzyme B. Our information present that CAFs inhibit NK cell activation by lowering their proliferation charges, the cytotoxic capability, the extent of degranulation, and the floor expression of stimulatory receptors, whereas concomitantly enhancing floor expression of inhibitory receptors.

Radiation delivered as single high-dose or in fractioned regimens didn’t reverse the immunosuppressive options exerted by CAFs over NK cells in vitro, regardless of triggering enhanced floor expression of a number of checkpoint ligands on irradiated CAFs. In abstract, CAFs mediate noticeable immune inhibitory results on cytokine-activated NK cells throughout co-culture in a donor-independent method. However, ionizing radiation doesn’t intervene with the CAF-mediated immunosuppressive results.

To study the cross-talk between NK cells and DCs in HCV an infection, we remoted monocytes and NK cells from 20 persistent HCV sufferers and 20 wholesome controls. Monocytes had been used to generate immature DCs which had been pulsed with HCV peptides (core, NS3-NS4 and NS5). Four totally different co-cultures had been carried out: E1: each DCs and NK cells had been from a persistent HCV affected person, E2: NK cells from a wholesome management co-cultured with DCs from a persistent HCV affected person, E3:

NK cells from a persistent HCV affected person co-cultured with DCs cells from a wholesome management and E4: each DCs and NK cells had been from a wholesome management. Using stream cytometry, we assessed the impact of those totally different co-cultures on ranges of maturation markers on DCs and ranges of activation/inhibition markers on NK cells. Results confirmed that peptide pulsed HCV DCs confirmed a maturation defect within the type of decreased HLA-DR, decreased CD86 and elevated CD83 expression particularly when co-cultured with HCV NK.

This was primarily as a result of core peptide pulsing and to a lesser extent as a result of NS5 pulsing whereas there was no impact with NS3-NS4 pulsing. Alternatively, HCV NK cells upregulated each activation and inhibition markers particularly when co-cultured with wholesome DCs. Compared to E2, E1 resulted in greater apoptosis of each NK cells and DCs with the proportion of NK apoptosis greater than that of DCs. Taken collectively, the information point out that HCV an infection impairs NK-DC cross-talk which can be a number one trigger in viral persistence and chronicity. This article is protected by copyright. All rights reserved.

Immune checkpoint molecules in pure killer cells as potential targets for most cancers immunotherapy

Recent research have demonstrated the potential of pure killer (NK) cells in immunotherapy to deal with a number of sorts of most cancers. NK cells are innate lymphoid cells that play important roles in tumor surveillance and management that effectively kill the tumor and don’t require the foremost histocompatibility complicated. The discovery of the NK’s potential as a promising therapeutic goal for most cancers is a reduction to oncologists as they face the problem of elevated chemo-resistant cancers. NK cells present nice potential towards stable and hematologic tumors and have progressively proven promise as a therapeutic goal for most cancers immunotherapy. The effector function of those cells is reliant on the steadiness of inhibitory and activating alerts.

Understanding the function of assorted immune checkpoint molecules within the exhaustion and impairment of NK cells when their inhibitory receptors are excessively expressed is especially necessary in most cancers immunotherapy research and scientific implementation. Emerging immune checkpoint receptors and molecules have been discovered to mediate NK cell dysfunction within the tumor microenvironment; this has introduced up the necessity to discover additional further NK cell-related immune checkpoints which may be exploited to reinforce the immune response to refractory cancers. Accordingly, this evaluate will give attention to the current findings in regards to the roles of immune checkpoint molecules and receptors within the regulation of NK cell operate, in addition to their potential software in tumor immunotherapy.

Irradiated Tumor Fibroblasts Avoid Immune Recognition and Retain Immunosuppressive Functions Over Natural Killer Cells

Natural Killer Cells in Immunotherapy: Are We Nearly There?

atural killer (NK) cells are potent anti-tumor and anti-microbial cells of our innate immune system. They are geared up with an unlimited array of receptors that acknowledge tumor cells and different pathogens. The innate immune exercise of NK cells develops sooner than the adaptive one carried out by T cells, and research counsel an necessary immunoregulatory function for every inhabitants towards the opposite.

The affiliation, noticed in acute myeloid leukemia sufferers receiving haploidentical killer-immunoglobulin-like-receptor-mismatched NK cells, with induction of full remission was the determinant to start an growing variety of scientific research administering NK cells for the therapy of most cancers sufferers. Unfortunately, though transfused NK cells demonstrated security, their noticed efficacy was poor.

Alpha-bungarotoxin, CF405s

00002-100ug 100uG
EUR 161
Description: Minimum order quantity: 1 unit of 100uG

Alpha-bungarotoxin, CF680r

9-00003
  • EUR 494.00
  • EUR 161.00
  • 500uG
  • 100uG
Description: Minimum order quantity: 1 unit of 500uG

Alpha-bungarotoxin, CF680r

9-00003
  • EUR 494.00
  • EUR 161.00
  • 500uG
  • 100uG
Description: Minimum order quantity: 1 unit of 100uG

Alpha-bungarotoxin, CF640r

9-00004
  • EUR 494.00
  • EUR 161.00
  • 500uG
  • 100uG
Description: Minimum order quantity: 1 unit of 500uG

Alpha-bungarotoxin, CF640r

9-00004
  • EUR 494.00
  • EUR 161.00
  • 500uG
  • 100uG
Description: Minimum order quantity: 1 unit of 100uG

Alpha-bungarotoxin, CF488a

9-00005
  • EUR 494.00
  • EUR 161.00
  • 500uG
  • 100uG
Description: Minimum order quantity: 1 unit of 500uG

Alpha-bungarotoxin CF488a

9-00005
  • EUR 494.00
  • EUR 161.00
  • 500uG
  • 100uG
Description: Minimum order quantity: 1 unit of 100uG

Alpha-bungarotoxin, CF568

9-00006
  • EUR 494.00
  • EUR 161.00
  • 500uG
  • 100uG
Description: Minimum order quantity: 1 unit of 500uG

Alpha-bungarotoxin, CF568

9-00006
  • EUR 494.00
  • EUR 161.00
  • 500uG
  • 100uG
Description: Minimum order quantity: 1 unit of 100uG

Alpha-bungarotoxin, CF594

9-00007
  • EUR 494.00
  • EUR 161.00
  • 500uG
  • 100uG
Description: Minimum order quantity: 1 unit of 500uG

Alpha-bungarotoxin CF594

9-00007
  • EUR 494.00
  • EUR 161.00
  • 500uG
  • 100uG
Description: Minimum order quantity: 1 unit of 100uG

Alpha-bungarotoxin, CF633

9-00009
  • EUR 494.00
  • EUR 161.00
  • 500uG
  • 100uG
Description: Minimum order quantity: 1 unit of 500uG

Alpha-bungarotoxin, CF633

9-00009
  • EUR 494.00
  • EUR 161.00
  • 500uG
  • 100uG
Description: Minimum order quantity: 1 unit of 100uG

Alpha-bungarotoxin

00010-1 1MG
EUR 168
Description: Minimum order quantity: 1 unit of 1MG

Fluorescein-Alpha-bungarotoxin

00011 500uG
EUR 367
Description: Minimum order quantity: 1 unit of 500uG

Tetramethylrhodamine-Alpha-bungarotoxin

00012 500uG
EUR 383
Description: Minimum order quantity: 1 unit of 500uG

Fluorescein-alpha-bungarotoxin: (10x50ug)

00013 10ST
EUR 417
Description: Minimum order quantity: 1 unit of 10ST

Tetramethylrhodamine-alpha-bungarotoxin: (10x50ug)

00014 10ST
EUR 466
Description: Minimum order quantity: 1 unit of 10ST

Sulforhodamine 101-a-bungarotoxin (Texas Red--a-bungarotoxin): (500ug)

00015 500uG
EUR 466
Description: Minimum order quantity: 1 unit of 500uG

Sulforhodamine 101-a-bungarotoxin (Texas Red--a-bungarotoxin): (10x50ug)

00016 10ST
EUR 523
Description: Minimum order quantity: 1 unit of 10ST

Biotin-xx-a-bungarotoxin

00017 500uG
EUR 433
Description: Minimum order quantity: 1 unit of 500uG

Alpha-Bungarotoxin, CF555 conjugate

9-00018
  • EUR 494.00
  • EUR 161.00
  • 500uG
  • 100ug
Description: Minimum order quantity: 1 unit of 500uG

Alpha-Bungarotoxin, CF555 conjugate

9-00018
  • EUR 494.00
  • EUR 161.00
  • 500uG
  • 100ug
Description: Minimum order quantity: 1 unit of 100ug

Biotin-cAMP, diisopropylethylammonium salt:

00020 1MG
EUR 314
Description: Minimum order quantity: 1 unit of 1MG

Biotin-cAMP, diisopropylethylammonium salt: (20x50ug)

00020-1 20ST
EUR 418
Description: Minimum order quantity: 1 unit of 20ST

Biotin-cGMP, diisopropylethylammonium salt:

00021 1MG
EUR 344
Description: Minimum order quantity: 1 unit of 1MG

Biotin-cGMP, diisopropylethylammonium salt: (20x50ug)

00021-1 20ST
EUR 448
Description: Minimum order quantity: 1 unit of 20ST

Cyanine 644-cAMP:

00022 1MG
EUR 491
Description: Minimum order quantity: 1 unit of 1MG

Cyanine 644-cAMP: (20x50ug)

00022-1 20ST
EUR 625
Description: Minimum order quantity: 1 unit of 20ST

Fluorescein Methotrexate, triammonium salt:

00023 1MG
EUR 281
Description: Minimum order quantity: 1 unit of 1MG

Staurosporine

00025 100uG
EUR 139
Description: Minimum order quantity: 1 unit of 100uG

Alpha-bungarotoxin, CF543

00026 500uG
EUR 494
Description: Minimum order quantity: 1 unit of 500uG

Rhodamine phalloidin 300u

00027 300
EUR 345
Description: Minimum order quantity: 1 unit of 300

Biotin-xx-phalloidin

00028 100U
EUR 428
Description: Minimum order quantity: 1 unit of 100U

Fluorescein-phalloidin

00030 300U
EUR 345
Description: Minimum order quantity: 1 unit of 300U

Rhodamine 110 phalloidin

00032 300ST
EUR 345
Description: Minimum order quantity: 1 unit of 300ST

Sulforhodamine 101 (Texas-Red) Phalloidin

00033 300EU
EUR 345
Description: Minimum order quantity: 1 unit of 300EU

Phalloidin, CF405M

00034 300U
EUR 442
Description: Minimum order quantity: 1 unit of 300U

Phalloidin, CF405M

00034-T 50U
EUR 133
Description: Minimum order quantity: 1 unit of 50U

CF488A-cAMP

00036 100ug
EUR 172
Description: Minimum order quantity: 1 unit of 100ug

CF640R-cAMP

00037 100ug
EUR 172
Description: Minimum order quantity: 1 unit of 100ug

Phalloidin, CF555

00040 300U
EUR 442
Description: Minimum order quantity: 1 unit of 300U

Phalloidin, CF555

00040-T 50U
EUR 133
Description: Minimum order quantity: 1 unit of 50U

Phalloidin, CF647

00041 300U
EUR 442
Description: Minimum order quantity: 1 unit of 300U

Phalloidin, CF647

00041-T 50U
EUR 133
Description: Minimum order quantity: 1 unit of 50U

Phalloidin, CF488A

00042 300U
EUR 442
Description: Minimum order quantity: 1 unit of 300U

Phalloidin, CF488A

00042-T 50U
EUR 133
Description: Minimum order quantity: 1 unit of 50U

Phalloidin, CF543

00043 300U
EUR 442
Description: Minimum order quantity: 1 unit of 300U

Phalloidin, CF543

00043-T 50U
EUR 133
Description: Minimum order quantity: 1 unit of 50U

Phalloidin, CF568

00044 300U
EUR 442
Description: Minimum order quantity: 1 unit of 300U

Phalloidin, CF568

00044-T 50U
EUR 133
Description: Minimum order quantity: 1 unit of 50U

Phalloidin, CF594

00045 300U
EUR 442
Description: Minimum order quantity: 1 unit of 300U

Phalloidin, CF594

00045-T 50U
EUR 133
Description: Minimum order quantity: 1 unit of 50U

Phalloidin, CF633

00046 300U
EUR 442
Description: Minimum order quantity: 1 unit of 300U

Phalloidin, CF633

00046-T 50U
EUR 133
Description: Minimum order quantity: 1 unit of 50U

Phalloidin, CF660R

00047 300U
EUR 442
Description: Minimum order quantity: 1 unit of 300U

Phalloidin, CF660R

00047-T 50U
EUR 133
Description: Minimum order quantity: 1 unit of 50U

Phalloidin, CF680R

00048 300U
EUR 466
Description: Minimum order quantity: 1 unit of 300U

Phalloidin, CF680R

00048-T 50U
EUR 133
Description: Minimum order quantity: 1 unit of 50U

Phalloidin, CF350

00049 300U
EUR 442
Description: Minimum order quantity: 1 unit of 300U

Phalloidin, CF350

00049-T 50U
EUR 133
Description: Minimum order quantity: 1 unit of 50U

Phalloidin, CF640R

00050 300U
EUR 442
Description: Minimum order quantity: 1 unit of 300U

Phalloidin, CF640R

00050-T 50U
EUR 133
Description: Minimum order quantity: 1 unit of 50U

Phalloidin, CF532

00051 300U
EUR 442
Description: Minimum order quantity: 1 unit of 300U

Phalloidin, CF532

00051-T 50U
EUR 133
Description: Minimum order quantity: 1 unit of 50U

Phalloidin, CF660C

00052 300U
EUR 442
Description: Minimum order quantity: 1 unit of 300U

Phalloidin, CF660C

00052-T 50U
EUR 133
Description: Minimum order quantity: 1 unit of 50U

Phalloidin, CF680

00053 300U
EUR 466
Description: Minimum order quantity: 1 unit of 300U

Phalloidin, CF680

00053-T 50U
EUR 147
Description: Minimum order quantity: 1 unit of 50U

Phalloidin, CF430

00054 300U
EUR 449
Description: Minimum order quantity: 1 unit of 300U

Phalloidin, CF430

00054-T 50U
EUR 139
Description: Minimum order quantity: 1 unit of 50U

Phalloidin, CF440

00055 300U
EUR 449
Description: Minimum order quantity: 1 unit of 300U

Phalloidin, CF440

00055-T 50U
EUR 139
Description: Minimum order quantity: 1 unit of 50U

Cholera Toxin Subunit B, CF488A conjugate

00070 100ug
EUR 261
Description: Minimum order quantity: 1 unit of 100ug

Cholera Toxin Subunit B, CF568 conjugate

00071 100ug
EUR 261
Description: Minimum order quantity: 1 unit of 100ug

Cholera Toxin Subunit B, CF594 conjugate

00072 100ug
EUR 261
Description: Minimum order quantity: 1 unit of 100ug

Cholera Toxin Subunit B, CF640R conjugate

00073 100ug
EUR 264
Description: Minimum order quantity: 1 unit of 100ug

Cholera Toxin Subunit B, CF532 conjugate

00074 100ug
EUR 264
Description: Minimum order quantity: 1 unit of 100ug

Cholera Toxin Subunit B, CF543 conjugate

00075 100ug
EUR 264
Description: Minimum order quantity: 1 unit of 100ug

Cholera Toxin Subunit B, CF620R conjugate

00076 100ug
EUR 264
Description: Minimum order quantity: 1 unit of 100ug

Cholera Toxin Subunit B, CF633 conjugate

00077 100ug
EUR 264
Description: Minimum order quantity: 1 unit of 100ug

Cholera Toxin Subunit B, CF660R conjugate

00078 100ug
EUR 264
Description: Minimum order quantity: 1 unit of 100ug

Cholera Toxin Subunit B, CF680R conjugate

00079 100ug
EUR 282
Description: Minimum order quantity: 1 unit of 100ug

Human Transferrin, CF488A conjugate

00081 1mg
EUR 149
Description: Minimum order quantity: 1 unit of 1mg

Human Transferrin, CF543 conjugate

00082 1mg
EUR 149
Description: Minimum order quantity: 1 unit of 1mg

Human Transferrin, CF568 conjugate

00083 1mg
EUR 149
Description: Minimum order quantity: 1 unit of 1mg

Human Transferrin, CF594 conjugate

00084 1mg
EUR 149
Description: Minimum order quantity: 1 unit of 1mg

Human Transferrin, CF640R conjugate

00085 1mg
EUR 149
Description: Minimum order quantity: 1 unit of 1mg

Human Transferrin, CF680R conjugate

00086 1mg
EUR 149
Description: Minimum order quantity: 1 unit of 1mg

Human Transferrin, CF750 conjugate

00087 1mg
EUR 155
Description: Minimum order quantity: 1 unit of 1mg

HIV-1 tat recombinant antigen

00110-V-01mg 0,1 mg
EUR 267.5
Description: HIV-1 tat recombinant antigen full length 15 kDa

HIV-1 tat recombinant antigen

00110-V-1000ug 1000 ug
EUR 1282.5
Description: HIV-1 tat recombinant antigen full length 15 kDa

HIV-1 GAG P24 Recombinant Antigen

00111-V-01mg 0,1 mg
EUR 267.5
Description: HIV-1 gag p24 recombinant antigen a.a 77 to a.a 436 of the HIV-1 gag region 39 kDa

HIV-1 GAG P24 Recombinant Antigen

00111-V-1000ug 1000 ug
EUR 1282.5
Description: HIV-1 gag p24 recombinant antigen a.a 77 to a.a 436 of the HIV-1 gag region 39 kDa

HIV-1 nef recombinant antigen

00112-V-01mg 0,1 mg
EUR 267.5
Description: HIV-1 nef recombinant antigen a.a 3 to a.a 190 of the HIV-1 nef region 20 kDa

HIV-1 nef recombinant antigen

00112-V-1000ug 1000 ug
EUR 1282.5
Description: HIV-1 nef recombinant antigen a.a 3 to a.a 190 of the HIV-1 nef region 20 kDa

HIV-1 env gp41 recombinant antigen

00113-V-01mg 0,1 mg
EUR 267.5
Description: HIV-1 env gp41 recombinant antigen a.a 466 to a.a 753 of the HIV-1 env region 32 kDa

HIV-1 env gp41 recombinant antigen

00113-V-1000ug 1000 ug
EUR 1282.5
Description: HIV-1 env gp41 recombinant antigen a.a 466 to a.a 753 of the HIV-1 env region 32 kDa

HIV-2 GP 36 Recombinant Antigen

00114-V-01mg 0,1 mg
EUR 267.5
Description: HIV -2 env gp36 recombinant antigen a.a 390 to a.a 702 of the HIV-2 env region 34 kDa

HIV-2 GP 36 Recombinant Antigen

00114-V-1000ug 1000 ug
EUR 1282.5
Description: HIV -2 env gp36 recombinant antigen a.a 390 to a.a 702 of the HIV-2 env region 34 kDa

HCV core recombinant antigen

00115-V-01mg 0,1 mg
EUR 267.5
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa

HCV core recombinant antigen

00115-V-1000ug 1000 ug
EUR 1282.5
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa

HCV core recombinant antigen, Biotin conjugate

00115-V-B-01mg 0,1 mg
EUR 267.5
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa. Biotin conjugate.

HCV core recombinant antigen, Biotin conjugate

00115-V-B-1000ug 1000 ug
EUR 1282.5
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa. Biotin conjugate.

HCV core recombinant antigen, FITC conjugate

00115-V-F-01mg 0,1 mg
EUR 267.5
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa. Fluorescein conjugate.

HCV core recombinant antigen, FITC conjugate

00115-V-F-1000ug 1000 ug
EUR 1282.5
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa. Fluorescein conjugate.

HCV core recombinant antigen, Rhodamine

00115-V-R-01mg 0,1 mg
EUR 267.5
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa . Rhodamine conjugate.

HCV core recombinant antigen, Rhodamine

00115-V-R-1000ug 1000 ug
EUR 1282.5
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa . Rhodamine conjugate.

HCV NS4 recombinant antigen NS4a+b

00116-V-01mg 0,1 mg
EUR 267.5
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa.

HCV NS4 recombinant antigen NS4a+b

00116-V-1000ug 1000 ug
EUR 1282.5
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa.

HCV NS4 recombinant antigen NS4a+b, Biotin

00116-V-B-01mg 0,1 mg
EUR 267.5
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Biotin conjugate.

HCV NS4 recombinant antigen NS4a+b, Biotin

00116-V-B-1000ug 1000 ug
EUR 1282.5
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Biotin conjugate.

HCV NS4 recombinant antigen NS4a+b, FITC

00116-V-F-01mg 0,1 mg
EUR 267.5
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Fluorescein conjugate.

HCV NS4 recombinant antigen NS4a+b, FITC

00116-V-F-1000ug 1000 ug
EUR 1282.5
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Fluorescein conjugate.

HCV NS4 recombinant antigen NS4a+b, Rhodamine

00116-V-R-01mg 0,1 mg
EUR 267.5
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Rhodamine conjugate.

HCV NS4 recombinant antigen NS4a+b, Rhodamine

00116-V-R-1000ug 1000 ug
EUR 1282.5
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Rhodamine conjugate.

HCV NS3 recombinant antigen

00117-V-01mg 0,1 mg
EUR 267.5
Description: HCV NS3 recombinant antigen a.a 1400 to a.a 1643 of HCV polyprotein 22 kDa

HCV NS3 recombinant antigen

00117-V-1000ug 1000 ug
EUR 1282.5
Description: HCV NS3 recombinant antigen a.a 1400 to a.a 1643 of HCV polyprotein 22 kDa

HBV core recombinant antigen

00120-V-01mg 0,1 mg
EUR 267.5
Description: HBV core recombinant antigen HBcAg a.a 1 to a.a 183 of HBV core antigen 18 kDa

HBV core recombinant antigen

00120-V-1000ug 1000 ug
EUR 1282.5
Description: HBV core recombinant antigen HBcAg a.a 1 to a.a 183 of HBV core antigen 18 kDa

HBV core recombinant antigen, Delta

00121-V-01mg 0,1 mg
EUR 267.5
Description: HBV core recombinant antigen HBcAg a.a 1 to a.a 144 of HBV core antigen 16 kDa

HBV core recombinant antigen, Delta

00121-V-1000ug 1000 ug
EUR 1282.5
Description: HBV core recombinant antigen HBcAg a.a 1 to a.a 144 of HBV core antigen 16 kDa

HBV surface recombinant antigen HBsAg

00122-V-01mg 0,1 mg
EUR 267.5
Description: HBV surface recombinant antigen HBsAg antigen 22 kDa Pichia pastoris recombinant

In current years, novel research have emerged, combining NK cells with different immunotherapeutic brokers, reminiscent of monoclonal antibodies, which could enhance scientific efficacy. Moreover, genetically-modified NK cells aimed toward arming NK cells with higher efficacy and persistence have appeared as another choice. Here, we evaluate novel pre-clinical and scientific research printed within the final 5 years administering NK cells as a monotherapy and mixed with different brokers, and we additionally evaluate chimeric antigen receptor-modified NK cells for the therapy of most cancers sufferers.

Antibodies, Assay Kits, cDNA, Cell-to-cell contact with hepatitis C virus-infected cells reduces functional capacity of natural killer cells, Chronic shift-lag alters the circadian clock of NK cells and promotes lung cancer growth in rats, Culture Cells, Delineation and Modulation of the Natural Killer Cell Transcriptome in Rhesus Macaques During ZIKV and SIV Infections., Devices, DNA Templates, DNA Testing, Elisa Kits, Enzymes, Equipments, Functions of natural killer cells, Gels, General, Healthy Neonates Possess a CD56-Negative NK Cell Population with Reduced Anti-Viral Activity, Human mesenchymal stem cells modulate allogeneic immune cell responses, Human NK cells kill resting but not activated microglia via NKG2D- and NKp46-mediated recognition, Isotypes, Medium & Serums, Overview of Strategies to Improve Therapy against Tumors Using Natural Killer Cell., Panel, Particles, Pcr Kits, Peptides, Reagents, Ria Kits, RNA, TRP Channels as Interior Designers: Remodeling the Endolysosomal Compartment in Natural Killer Cells.

The Role of the Cytoskeleton in Regulating the Natural Killer Cell Immune Response in Health and Disease: From Signaling Dynamics to Function

Natural killer (NK) cells are innate lymphoid cells, which play key roles in elimination of virally contaminated and malignant cells. The steadiness between activating and inhibitory alerts derived from NK floor receptors govern the NK cell immune response. The cytoskeleton facilitates most NK cell effector capabilities, akin to motility, infiltration, conjugation with goal cells, immunological synapse meeting, and cytotoxicity. Though many research have characterised signaling pathways that promote actin reorganization in immune cells, it isn’t utterly clear how specific cytoskeletal architectures at the immunological synapse promote effector capabilities, and how cytoskeletal dynamics influence downstream signaling pathways and activation.

Moreover, pioneering research using superior imaging methods have solely begun to uncover the architectural complexity dictating the NK cell activation threshold; it’s changing into clear {that a} distinct group of the cytoskeleton and signaling receptors at the NK immunological synapse performs a decisive position in activation and tolerance. Here, we evaluate the roles of the actin cytoskeleton in NK cells. We deal with how actin dynamics influence cytolytic granule secretion, NK cell motility, and NK cell infiltration by way of tissues into inflammatory websites. We can even describe the further cytoskeletal elements, non-muscle Myosin II and microtubules that play pivotal roles in NK cell exercise.

Expression of programmed cell loss of life protein 1 (PD-1) on pure killer (NK) cells has been tough to analyze on human NK cells. By testing industrial clones and novel anti-PD-1 reagents, we discovered expression of practical PD-1 on resting human NK cells in wholesome people and reconstituting NK cells early after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Peripheral blood samples from wholesome people and transplant recipients had been stained for PD-1 expression utilizing the industrial anti-PD-1 clone PD1.3.1.3, fluorescein isothiocyanate (FITC)-labeled pembrolizumab, or an FITC-labeled single-chain variable fragment (scFv) reagent comprised of pembrolizumab.
These reagents recognized low but constant basal PD-1 expression on resting NK cells, a discovering verified by discovering decrease PD-1 transcripts in sorted NK cells in contrast with these in resting or activated T cells. An enhance in PD-1 expression was recognized on paired resting NK cells after allo-HSCT. Blockade of PD-1 on resting NK cells from wholesome donors with pembrolizumab didn’t improve NK operate towards programmed death-ligand 1 (PD-L1)-expressing tumor traces, however blocking with its scFv by-product resulted in a twofold enhance in NK cell degranulation and up to a fourfold enhance in cytokine manufacturing.
In assist of this mechanism, PD-L1 overexpression of Okay562 targets suppressed NK cell operate. Interleukin-15 (IL-15) exercise was potent and couldn’t be additional enhanced by PD-1 blockade. An identical enhance in operate was noticed with scFv PD-1 blockade on resting blood NK cells after allo-HSCT. We determine the practical significance of the PD-1/PD-L1 axis on human NK cells in which blockade or activation to overcome inhibition will improve NK cell-mediated antitumor management. Furthermore, particular emphasis might be positioned on the position of the cytoskeleton in meeting of immunological synapses, and how mutations or downregulation of cytoskeletal accent proteins influence NK cell operate in well being and illness.
The Role of the Cytoskeleton in Regulating the Natural Killer Cell Immune Response in Health and Disease: From Signaling Dynamics to Function

Lack of Viral Load Within Chronic Lymphoproliferative Disorder of Natural Killer Cells: What Is Outside the Leukemic Clone?

 

Large granular lymphocyte leukemias (LGLL) are sustained by proliferating cytotoxic T cells or NK cells, as occurs in Chronic Lymphoproliferative Disorder of Natural Killer cells (CLPD-NK), whose etiology is simply partly understood. Different hypotheses have been proposed on the unique occasions triggering NK cell hyperactivation and transformation, together with a job of viral brokers. In this angle, we revise the traces of proof that steered a pathogenetic position in LGLL of the publicity to retroviruses and that recognized Epstein Barr Virus (EBV) in different NK cell leukemias and lymphomas and deal with the contrasting information about the significance of viral brokers in CLPD-NK.

EBV was detected in aggressive NK leukemias however not in the indolent CLPD-NK, the place seroreactivity towards HTLV-1 retrovirus envelope BA21 protein antigens has been reported in sufferers, though missing clear proof of HTLV an infection. We subsequent current unique outcomes of complete exome sequencing information evaluation that failed to determine viral sequences in CLPD-NK. We not too long ago demonstrated that proliferating NK cells of sufferers harbor a number of somatic lesions probably contributing to maintain NK cell proliferation.

Thus, we discover whether or not “neoantigens” comparable to the BA21 antigen might be generated by aberrancies current in the leukemic clone. In gentle of the literature and new information, we evaluated the intriguing speculation that NK cell activation will be attributable to retroviral brokers situated outdoors the hematopoietic compartment and on the potential mechanisms concerned with the prospects of immunotherapy-based approaches to restrict the progress of NK cells in CLPD-NK illness.

Alpha-bungarotoxin, CF405s

00002-100ug 100uG
EUR 161
Description: Minimum order quantity: 1 unit of 100uG

Alpha-bungarotoxin, CF680r

9-00003
  • EUR 494.00
  • EUR 161.00
  • 500uG
  • 100uG
Description: Minimum order quantity: 1 unit of 500uG

Alpha-bungarotoxin, CF680r

9-00003
  • EUR 494.00
  • EUR 161.00
  • 500uG
  • 100uG
Description: Minimum order quantity: 1 unit of 100uG

Alpha-bungarotoxin, CF640r

9-00004
  • EUR 494.00
  • EUR 161.00
  • 500uG
  • 100uG
Description: Minimum order quantity: 1 unit of 500uG

Alpha-bungarotoxin, CF640r

9-00004
  • EUR 494.00
  • EUR 161.00
  • 500uG
  • 100uG
Description: Minimum order quantity: 1 unit of 100uG

Alpha-bungarotoxin, CF488a

9-00005
  • EUR 494.00
  • EUR 161.00
  • 500uG
  • 100uG
Description: Minimum order quantity: 1 unit of 500uG

Alpha-bungarotoxin CF488a

9-00005
  • EUR 494.00
  • EUR 161.00
  • 500uG
  • 100uG
Description: Minimum order quantity: 1 unit of 100uG

Alpha-bungarotoxin, CF568

9-00006
  • EUR 494.00
  • EUR 161.00
  • 500uG
  • 100uG
Description: Minimum order quantity: 1 unit of 500uG

Alpha-bungarotoxin, CF568

9-00006
  • EUR 494.00
  • EUR 161.00
  • 500uG
  • 100uG
Description: Minimum order quantity: 1 unit of 100uG

Alpha-bungarotoxin, CF594

9-00007
  • EUR 494.00
  • EUR 161.00
  • 500uG
  • 100uG
Description: Minimum order quantity: 1 unit of 500uG

Alpha-bungarotoxin CF594

9-00007
  • EUR 494.00
  • EUR 161.00
  • 500uG
  • 100uG
Description: Minimum order quantity: 1 unit of 100uG

Alpha-bungarotoxin, CF633

9-00009
  • EUR 494.00
  • EUR 161.00
  • 500uG
  • 100uG
Description: Minimum order quantity: 1 unit of 500uG

Alpha-bungarotoxin, CF633

9-00009
  • EUR 494.00
  • EUR 161.00
  • 500uG
  • 100uG
Description: Minimum order quantity: 1 unit of 100uG

Alpha-bungarotoxin

00010-1 1MG
EUR 168
Description: Minimum order quantity: 1 unit of 1MG

Fluorescein-Alpha-bungarotoxin

00011 500uG
EUR 367
Description: Minimum order quantity: 1 unit of 500uG

Tetramethylrhodamine-Alpha-bungarotoxin

00012 500uG
EUR 383
Description: Minimum order quantity: 1 unit of 500uG

Fluorescein-alpha-bungarotoxin: (10x50ug)

00013 10ST
EUR 417
Description: Minimum order quantity: 1 unit of 10ST

Tetramethylrhodamine-alpha-bungarotoxin: (10x50ug)

00014 10ST
EUR 466
Description: Minimum order quantity: 1 unit of 10ST

Sulforhodamine 101-a-bungarotoxin (Texas Red--a-bungarotoxin): (500ug)

00015 500uG
EUR 466
Description: Minimum order quantity: 1 unit of 500uG

Sulforhodamine 101-a-bungarotoxin (Texas Red--a-bungarotoxin): (10x50ug)

00016 10ST
EUR 523
Description: Minimum order quantity: 1 unit of 10ST

Biotin-xx-a-bungarotoxin

00017 500uG
EUR 433
Description: Minimum order quantity: 1 unit of 500uG

Alpha-Bungarotoxin, CF555 conjugate

9-00018
  • EUR 494.00
  • EUR 161.00
  • 500uG
  • 100ug
Description: Minimum order quantity: 1 unit of 500uG

Alpha-Bungarotoxin, CF555 conjugate

9-00018
  • EUR 494.00
  • EUR 161.00
  • 500uG
  • 100ug
Description: Minimum order quantity: 1 unit of 100ug

Biotin-cAMP, diisopropylethylammonium salt:

00020 1MG
EUR 314
Description: Minimum order quantity: 1 unit of 1MG

Biotin-cAMP, diisopropylethylammonium salt: (20x50ug)

00020-1 20ST
EUR 418
Description: Minimum order quantity: 1 unit of 20ST

Biotin-cGMP, diisopropylethylammonium salt:

00021 1MG
EUR 344
Description: Minimum order quantity: 1 unit of 1MG

Biotin-cGMP, diisopropylethylammonium salt: (20x50ug)

00021-1 20ST
EUR 448
Description: Minimum order quantity: 1 unit of 20ST

Cyanine 644-cAMP:

00022 1MG
EUR 491
Description: Minimum order quantity: 1 unit of 1MG

Cyanine 644-cAMP: (20x50ug)

00022-1 20ST
EUR 625
Description: Minimum order quantity: 1 unit of 20ST

Fluorescein Methotrexate, triammonium salt:

00023 1MG
EUR 281
Description: Minimum order quantity: 1 unit of 1MG

Staurosporine

00025 100uG
EUR 139
Description: Minimum order quantity: 1 unit of 100uG

Alpha-bungarotoxin, CF543

00026 500uG
EUR 494
Description: Minimum order quantity: 1 unit of 500uG

Rhodamine phalloidin 300u

00027 300
EUR 345
Description: Minimum order quantity: 1 unit of 300

Biotin-xx-phalloidin

00028 100U
EUR 428
Description: Minimum order quantity: 1 unit of 100U

Fluorescein-phalloidin

00030 300U
EUR 345
Description: Minimum order quantity: 1 unit of 300U

Rhodamine 110 phalloidin

00032 300ST
EUR 345
Description: Minimum order quantity: 1 unit of 300ST

Sulforhodamine 101 (Texas-Red) Phalloidin

00033 300EU
EUR 345
Description: Minimum order quantity: 1 unit of 300EU

Phalloidin, CF405M

00034 300U
EUR 442
Description: Minimum order quantity: 1 unit of 300U

Phalloidin, CF405M

00034-T 50U
EUR 133
Description: Minimum order quantity: 1 unit of 50U

CF488A-cAMP

00036 100ug
EUR 172
Description: Minimum order quantity: 1 unit of 100ug

CF640R-cAMP

00037 100ug
EUR 172
Description: Minimum order quantity: 1 unit of 100ug

Phalloidin, CF555

00040 300U
EUR 442
Description: Minimum order quantity: 1 unit of 300U

Phalloidin, CF555

00040-T 50U
EUR 133
Description: Minimum order quantity: 1 unit of 50U

Phalloidin, CF647

00041 300U
EUR 442
Description: Minimum order quantity: 1 unit of 300U

Phalloidin, CF647

00041-T 50U
EUR 133
Description: Minimum order quantity: 1 unit of 50U

Phalloidin, CF488A

00042 300U
EUR 442
Description: Minimum order quantity: 1 unit of 300U

Phalloidin, CF488A

00042-T 50U
EUR 133
Description: Minimum order quantity: 1 unit of 50U

Phalloidin, CF543

00043 300U
EUR 442
Description: Minimum order quantity: 1 unit of 300U

Phalloidin, CF543

00043-T 50U
EUR 133
Description: Minimum order quantity: 1 unit of 50U

Phalloidin, CF568

00044 300U
EUR 442
Description: Minimum order quantity: 1 unit of 300U

Phalloidin, CF568

00044-T 50U
EUR 133
Description: Minimum order quantity: 1 unit of 50U

Phalloidin, CF594

00045 300U
EUR 442
Description: Minimum order quantity: 1 unit of 300U

Phalloidin, CF594

00045-T 50U
EUR 133
Description: Minimum order quantity: 1 unit of 50U

Phalloidin, CF633

00046 300U
EUR 442
Description: Minimum order quantity: 1 unit of 300U

Phalloidin, CF633

00046-T 50U
EUR 133
Description: Minimum order quantity: 1 unit of 50U

Phalloidin, CF660R

00047 300U
EUR 442
Description: Minimum order quantity: 1 unit of 300U

Phalloidin, CF660R

00047-T 50U
EUR 133
Description: Minimum order quantity: 1 unit of 50U

Phalloidin, CF680R

00048 300U
EUR 466
Description: Minimum order quantity: 1 unit of 300U

Phalloidin, CF680R

00048-T 50U
EUR 133
Description: Minimum order quantity: 1 unit of 50U

Phalloidin, CF350

00049 300U
EUR 442
Description: Minimum order quantity: 1 unit of 300U

Phalloidin, CF350

00049-T 50U
EUR 133
Description: Minimum order quantity: 1 unit of 50U

Phalloidin, CF640R

00050 300U
EUR 442
Description: Minimum order quantity: 1 unit of 300U

Phalloidin, CF640R

00050-T 50U
EUR 133
Description: Minimum order quantity: 1 unit of 50U

Phalloidin, CF532

00051 300U
EUR 442
Description: Minimum order quantity: 1 unit of 300U

Phalloidin, CF532

00051-T 50U
EUR 133
Description: Minimum order quantity: 1 unit of 50U

Phalloidin, CF660C

00052 300U
EUR 442
Description: Minimum order quantity: 1 unit of 300U

Phalloidin, CF660C

00052-T 50U
EUR 133
Description: Minimum order quantity: 1 unit of 50U

Phalloidin, CF680

00053 300U
EUR 466
Description: Minimum order quantity: 1 unit of 300U

Phalloidin, CF680

00053-T 50U
EUR 147
Description: Minimum order quantity: 1 unit of 50U

Phalloidin, CF430

00054 300U
EUR 449
Description: Minimum order quantity: 1 unit of 300U

Phalloidin, CF430

00054-T 50U
EUR 139
Description: Minimum order quantity: 1 unit of 50U

Phalloidin, CF440

00055 300U
EUR 449
Description: Minimum order quantity: 1 unit of 300U

Phalloidin, CF440

00055-T 50U
EUR 139
Description: Minimum order quantity: 1 unit of 50U

Cholera Toxin Subunit B, CF488A conjugate

00070 100ug
EUR 261
Description: Minimum order quantity: 1 unit of 100ug

Cholera Toxin Subunit B, CF568 conjugate

00071 100ug
EUR 261
Description: Minimum order quantity: 1 unit of 100ug

Cholera Toxin Subunit B, CF594 conjugate

00072 100ug
EUR 261
Description: Minimum order quantity: 1 unit of 100ug

Cholera Toxin Subunit B, CF640R conjugate

00073 100ug
EUR 264
Description: Minimum order quantity: 1 unit of 100ug

Cholera Toxin Subunit B, CF532 conjugate

00074 100ug
EUR 264
Description: Minimum order quantity: 1 unit of 100ug

Cholera Toxin Subunit B, CF543 conjugate

00075 100ug
EUR 264
Description: Minimum order quantity: 1 unit of 100ug

Cholera Toxin Subunit B, CF620R conjugate

00076 100ug
EUR 264
Description: Minimum order quantity: 1 unit of 100ug

Cholera Toxin Subunit B, CF633 conjugate

00077 100ug
EUR 264
Description: Minimum order quantity: 1 unit of 100ug

Cholera Toxin Subunit B, CF660R conjugate

00078 100ug
EUR 264
Description: Minimum order quantity: 1 unit of 100ug

Cholera Toxin Subunit B, CF680R conjugate

00079 100ug
EUR 282
Description: Minimum order quantity: 1 unit of 100ug

Human Transferrin, CF488A conjugate

00081 1mg
EUR 149
Description: Minimum order quantity: 1 unit of 1mg

Human Transferrin, CF543 conjugate

00082 1mg
EUR 149
Description: Minimum order quantity: 1 unit of 1mg

Human Transferrin, CF568 conjugate

00083 1mg
EUR 149
Description: Minimum order quantity: 1 unit of 1mg

Human Transferrin, CF594 conjugate

00084 1mg
EUR 149
Description: Minimum order quantity: 1 unit of 1mg

Human Transferrin, CF640R conjugate

00085 1mg
EUR 149
Description: Minimum order quantity: 1 unit of 1mg

Human Transferrin, CF680R conjugate

00086 1mg
EUR 149
Description: Minimum order quantity: 1 unit of 1mg

Human Transferrin, CF750 conjugate

00087 1mg
EUR 155
Description: Minimum order quantity: 1 unit of 1mg

HIV-1 tat recombinant antigen

00110-V-01mg 0,1 mg
EUR 267.5
Description: HIV-1 tat recombinant antigen full length 15 kDa

HIV-1 tat recombinant antigen

00110-V-1000ug 1000 ug
EUR 1282.5
Description: HIV-1 tat recombinant antigen full length 15 kDa

HIV-1 GAG P24 Recombinant Antigen

00111-V-01mg 0,1 mg
EUR 267.5
Description: HIV-1 gag p24 recombinant antigen a.a 77 to a.a 436 of the HIV-1 gag region 39 kDa

HIV-1 GAG P24 Recombinant Antigen

00111-V-1000ug 1000 ug
EUR 1282.5
Description: HIV-1 gag p24 recombinant antigen a.a 77 to a.a 436 of the HIV-1 gag region 39 kDa

HIV-1 nef recombinant antigen

00112-V-01mg 0,1 mg
EUR 267.5
Description: HIV-1 nef recombinant antigen a.a 3 to a.a 190 of the HIV-1 nef region 20 kDa

HIV-1 nef recombinant antigen

00112-V-1000ug 1000 ug
EUR 1282.5
Description: HIV-1 nef recombinant antigen a.a 3 to a.a 190 of the HIV-1 nef region 20 kDa

HIV-1 env gp41 recombinant antigen

00113-V-01mg 0,1 mg
EUR 267.5
Description: HIV-1 env gp41 recombinant antigen a.a 466 to a.a 753 of the HIV-1 env region 32 kDa

HIV-1 env gp41 recombinant antigen

00113-V-1000ug 1000 ug
EUR 1282.5
Description: HIV-1 env gp41 recombinant antigen a.a 466 to a.a 753 of the HIV-1 env region 32 kDa

HIV-2 GP 36 Recombinant Antigen

00114-V-01mg 0,1 mg
EUR 267.5
Description: HIV -2 env gp36 recombinant antigen a.a 390 to a.a 702 of the HIV-2 env region 34 kDa

HIV-2 GP 36 Recombinant Antigen

00114-V-1000ug 1000 ug
EUR 1282.5
Description: HIV -2 env gp36 recombinant antigen a.a 390 to a.a 702 of the HIV-2 env region 34 kDa

HCV core recombinant antigen

00115-V-01mg 0,1 mg
EUR 267.5
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa

HCV core recombinant antigen

00115-V-1000ug 1000 ug
EUR 1282.5
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa

HCV core recombinant antigen, Biotin conjugate

00115-V-B-01mg 0,1 mg
EUR 267.5
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa. Biotin conjugate.

HCV core recombinant antigen, Biotin conjugate

00115-V-B-1000ug 1000 ug
EUR 1282.5
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa. Biotin conjugate.

HCV core recombinant antigen, FITC conjugate

00115-V-F-01mg 0,1 mg
EUR 267.5
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa. Fluorescein conjugate.

HCV core recombinant antigen, FITC conjugate

00115-V-F-1000ug 1000 ug
EUR 1282.5
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa. Fluorescein conjugate.

HCV core recombinant antigen, Rhodamine

00115-V-R-01mg 0,1 mg
EUR 267.5
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa . Rhodamine conjugate.

HCV core recombinant antigen, Rhodamine

00115-V-R-1000ug 1000 ug
EUR 1282.5
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa . Rhodamine conjugate.

HCV NS4 recombinant antigen NS4a+b

00116-V-01mg 0,1 mg
EUR 267.5
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa.

HCV NS4 recombinant antigen NS4a+b

00116-V-1000ug 1000 ug
EUR 1282.5
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa.

HCV NS4 recombinant antigen NS4a+b, Biotin

00116-V-B-01mg 0,1 mg
EUR 267.5
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Biotin conjugate.

HCV NS4 recombinant antigen NS4a+b, Biotin

00116-V-B-1000ug 1000 ug
EUR 1282.5
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Biotin conjugate.

HCV NS4 recombinant antigen NS4a+b, FITC

00116-V-F-01mg 0,1 mg
EUR 267.5
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Fluorescein conjugate.

HCV NS4 recombinant antigen NS4a+b, FITC

00116-V-F-1000ug 1000 ug
EUR 1282.5
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Fluorescein conjugate.

HCV NS4 recombinant antigen NS4a+b, Rhodamine

00116-V-R-01mg 0,1 mg
EUR 267.5
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Rhodamine conjugate.

HCV NS4 recombinant antigen NS4a+b, Rhodamine

00116-V-R-1000ug 1000 ug
EUR 1282.5
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Rhodamine conjugate.

HCV NS3 recombinant antigen

00117-V-01mg 0,1 mg
EUR 267.5
Description: HCV NS3 recombinant antigen a.a 1400 to a.a 1643 of HCV polyprotein 22 kDa

HCV NS3 recombinant antigen

00117-V-1000ug 1000 ug
EUR 1282.5
Description: HCV NS3 recombinant antigen a.a 1400 to a.a 1643 of HCV polyprotein 22 kDa

HBV core recombinant antigen

00120-V-01mg 0,1 mg
EUR 267.5
Description: HBV core recombinant antigen HBcAg a.a 1 to a.a 183 of HBV core antigen 18 kDa

HBV core recombinant antigen

00120-V-1000ug 1000 ug
EUR 1282.5
Description: HBV core recombinant antigen HBcAg a.a 1 to a.a 183 of HBV core antigen 18 kDa

HBV core recombinant antigen, Delta

00121-V-01mg 0,1 mg
EUR 267.5
Description: HBV core recombinant antigen HBcAg a.a 1 to a.a 144 of HBV core antigen 16 kDa

HBV core recombinant antigen, Delta

00121-V-1000ug 1000 ug
EUR 1282.5
Description: HBV core recombinant antigen HBcAg a.a 1 to a.a 144 of HBV core antigen 16 kDa

HBV surface recombinant antigen HBsAg

00122-V-01mg 0,1 mg
EUR 267.5
Description: HBV surface recombinant antigen HBsAg antigen 22 kDa Pichia pastoris recombinant

HBV surface recombinant antigen HBsAg

00122-V-1000ug 1000 ug
EUR 1282.5
Description: HBV surface recombinant antigen HBsAg antigen 22 kDa Pichia pastoris recombinant

HBV surface recombinant antigen HBsAg antigen

00123-V-01mg 0,1 mg
EUR 267.5
Description: HBV surface recombinant antigen HBsAg antigen 22 kDa Pichia pastoris recombinant High purity

HBV surface recombinant antigen HBsAg antigen

00123-V-1000ug 1000 ug
EUR 1282.5
Description: HBV surface recombinant antigen HBsAg antigen 22 kDa Pichia pastoris recombinant High purity

HBV surface recombinant antigen HBsAg antigen

00124-V-01mg 0,1 mg
EUR 267.5
Description: HBV surface recombinant antigen HBsAg antigen 31 kDa E. coli recombinant

HBV surface recombinant antigen HBsAg antigen

00124-V-1000ug 1000 ug
EUR 1282.5
Description: HBV surface recombinant antigen HBsAg antigen 31 kDa E. coli recombinant

HEV (Birma) ORF2 recombinant antigen

00131-V-01mg 0,1 mg
EUR 267.5
Description: HEV (Birma) ORF2 recombinant antigen a.a. 633 to a.a 659.

HEV (Birma) ORF2 recombinant antigen

00131-V-1000ug 1000 ug
EUR 1282.5
Description: HEV (Birma) ORF2 recombinant antigen a.a. 633 to a.a 659.

HEV (Birma) ORF2 recombinant antigen

00132-V-01mg 0,1 mg
EUR 267.5
Description: HEV (Birma) ORF2 recombinant antigen a.a. 403 to a.a 461.

HEV (Birma) ORF2 recombinant antigen

00132-V-1000ug 1000 ug
EUR 1282.5
Description: HEV (Birma) ORF2 recombinant antigen a.a. 403 to a.a 461.

This part 2 research with Simon’s two-stage design evaluated daratumumab in sufferers with histologically confirmed extranodal NKTCL, nasal kind, per WHO classification that was refractory to or relapsed after ≥ 1 line of chemotherapy, who weren’t candidates for different remedy modalities. All sufferers obtained daratumumab 16 mg/kg intravenously as soon as weekly for Cycles 1 and 2, each different week for Cycles Three by way of 6, and each four weeks thereafter till development or unacceptable toxicity; all cycles had been 28 days. The main finish level was goal response price (ORR) based mostly on blinded impartial central evaluate per Revised Criteria for Response Assessment of Hodgkin and non-Hodgkin Lymphoma (Lugano classification).

Antibodies, Assay Kits, cDNA, Cell-to-cell contact with hepatitis C virus-infected cells reduces functional capacity of natural killer cells, Chronic shift-lag alters the circadian clock of NK cells and promotes lung cancer growth in rats, Clia Kits, Delineation and Modulation of the Natural Killer Cell Transcriptome in Rhesus Macaques During ZIKV and SIV Infections., Devices, DNA Templates, DNA Testing, Elisa Kits, Enzymes, Equipments, Functions of natural killer cells, Gels, General, Healthy Neonates Possess a CD56-Negative NK Cell Population with Reduced Anti-Viral Activity, Human mesenchymal stem cells modulate allogeneic immune cell responses, Human NK cells kill resting but not activated microglia via NKG2D- and NKp46-mediated recognition, Isotypes, Medium & Serums, Overview of Strategies to Improve Therapy against Tumors Using Natural Killer Cell., Panel, Particles, Pcr Kits, Peptides, Reagents, Ria Kits, RNA, TRP Channels as Interior Designers: Remodeling the Endolysosomal Compartment in Natural Killer Cells., Vector & Virus

Full Activation of Kinase Protein Kinase B by Phosphoinositide-Dependent Protein Kinase-1 and Mammalian Target of Rapamycin Complex 2 Is Required for Early Natural Killer Cell Development and Survival

The function of PI3K-mTOR pathway in regulating NK cell improvement has been extensively reported. However, it stays unclear whether or not NK cell improvement depends upon the protein kinase B (PKB), which hyperlinks PI3K and mTOR, maybe because of the potential redundancy of PKB. PKB has two phosphorylation websites, threonine 308 (T308) and serine 473 (S473), which may be phosphorylated by phosphoinositide-dependent protein kinase-1 (PDK1) and mTORC2, respectively. In this research, we established a mouse mannequin wherein PKB was inactivated by the deletion of PDK1 and Rictor, a key element of mTORC2, respectively.

We discovered that the only deletion of PDK1 or Rictor may result in a major defect in NK cell improvement, whereas mixed deletion of PDK1 and Rictor severely hindered NK cell improvement on the early stage. Notably, ectopic expression of myristoylated PKB considerably rescued this defect. In phrases of mechanism, in PDK1/Rictor-deficient NK cells, E4BP4, a transcription issue for NK cell improvement, was much less expressed, and the exogenous provide of E4BP4 may alleviate the developmental defect of NK cell in these mice. Besides, overexpression of Bcl-2 additionally helped the survival of PDK1/Rictor-deficient NK cells, suggesting an anti-apoptotic function of PKB in NK cells.

Natural killer (NK) cells and dendritic cells (DCs) are essential mediators of productive immune responses to an infection and illness. NK cells and a subtype of DCs, the kind 1 standard DCs (cDC1s), are individually essential for regulating immune responses to most cancers in mice and people. Recent work has discovered that NK cells and cDC1s interact in intercellular cross-talk integral to initiating and coordinating adaptive immunity to most cancers. This NK cell-cDC1 axis has been linked to elevated total survival and responses to anti-PD-1 immunotherapy in metastatic melanoma sufferers. Here, we evaluation latest findings on the function of NK cells and cDC1s in protecting immune responses to most cancers and immunotherapy, in addition to present therapies concentrating on this NK cell-cDC1 axis.

Further, we discover the idea that intercellular cross-talk between NK cells and cDC1s could also be key for many of the optimistic prognostic associations seen with NK cells and DCs individually. It is evident that rising our understanding of the NK cell-cDC1 innate immune cell axis shall be essential for the era of novel therapies that may modulate anti-cancer immunity and improve affected person responses to frequent immunotherapies. In abstract, full phosphorylation of PKB at T308 and S473 by PDK1 and mTORC2 is important for optimum NK cell improvement, and PKB regulates NK cell improvement by selling E4BP4 expression and stopping cell apoptosis.

Updating targets for pure killer/T-cell lymphoma immunotherapy

 

Natural killer/T-cell lymphoma (NKTCL) is a extremely invasive subtype of non-Hodgkin lymphoma, usually optimistic for cytoplasmic CD3, CD56, cytotoxic markers, together with granzyme B and TIA1, and Epstein-Barr virus (EBV). The present remedy strategies for NKTCL are related to a number of drawbacks. For instance, chemotherapy can result in drug resistance, whereas remedy with radiotherapy alone is insufficient and leads to frequent relapses.

Moreover, hematopoietic stem cell transplantation reveals restricted efficacy and shouldn’t be effectively acknowledged by home and international specialists. In latest years, immunotherapy has proven good medical outcomes and has grow to be a scorching spot in most cancers analysis. Clinical exercise of focused antibodies, equivalent to daratumumab (anti-CD38 antibody) and brentuximab vedotin (anti-CD30 antibody), have been reported in NKTCL. Additionally, dacetuzumab and Campath-1H have demonstrated promising outcomes. Further encouraging knowledge have been obtained utilizing checkpoint inhibitors.

The success of these immunotherapy brokers is attributed to excessive expression ranges of programmed death-ligand 1 in NKTCL. Furthermore, anti-CCR4 monoclonal antibodies (mAbs) exert cytotoxic actions on each CCR4+ tumor cells and regulatory T cells. Depletion of these cells and the lengthy half-life of anti-CCR4 mAbs end in enhanced induction of antitumor effector T cells. The function of IL10 in NKTCL has additionally been investigated. It has been proposed that exploitation of this cytokine may present potential novel therapeutic methods.

Cellular immunotherapy with engineered cytotoxic T lymphocytes focused towards LMP1 and LMP2 has proven promising outcomes and sustained remission. Cellular immunotherapy could also be used both as upkeep remedy following preliminary induction chemotherapy or in instances of relapsed/refractory illness. The current evaluation outlines the recognized immunotherapy targets for the remedy of NKTCL. This enrichment has had substantial enter by inhabitants admixture with neighboring populations, who contributed HLA class I haplotypes expressing the KIR ligands B*46:01 and B*58:01, which subsequently rose to excessive frequency by pure choice.

Full Activation of Kinase Protein Kinase B by Phosphoinositide-Dependent Protein Kinase-1 and Mammalian Target of Rapamycin Complex 2 Is Required for Early Natural Killer Cell Development and Survival

Adaptive Admixture of HLA class I Allotypes Enhanced Genetically Determined Strength of Natural Killer Cells in East Asians

Human pure killer (NK) cells are important for controlling an infection, most cancers and fetal improvement. NK cell features are modulated by interactions between polymorphic inhibitory killer cell immunoglobulin-like receptors (KIR) and polymorphic HLA-A, -B and -C ligands expressed on tissue cells. All HLA-C alleles encode a KIR ligand and contribute to replica and immunity. In distinction, just some HLA-A and -B alleles encode KIR ligands and they give attention to immunity. By high-resolution evaluation of KIR and HLA-A, -B and -C genes, we present that the Chinese Southern Han are considerably enriched for interactions between inhibitory KIR and HLA-A and -B.

Alpha-bungarotoxin, CF640r

9-00004
  • EUR 494.00
  • EUR 161.00
  • 500uG
  • 100uG
Description: Minimum order quantity: 1 unit of 100uG

Alpha-bungarotoxin, CF488a

9-00005
  • EUR 494.00
  • EUR 161.00
  • 500uG
  • 100uG
Description: Minimum order quantity: 1 unit of 500uG

Alpha-bungarotoxin CF488a

9-00005
  • EUR 494.00
  • EUR 161.00
  • 500uG
  • 100uG
Description: Minimum order quantity: 1 unit of 100uG

Alpha-bungarotoxin, CF568

9-00006
  • EUR 494.00
  • EUR 161.00
  • 500uG
  • 100uG
Description: Minimum order quantity: 1 unit of 500uG

Alpha-bungarotoxin, CF568

9-00006
  • EUR 494.00
  • EUR 161.00
  • 500uG
  • 100uG
Description: Minimum order quantity: 1 unit of 100uG

Alpha-bungarotoxin, CF594

9-00007
  • EUR 494.00
  • EUR 161.00
  • 500uG
  • 100uG
Description: Minimum order quantity: 1 unit of 500uG

Alpha-bungarotoxin CF594

9-00007
  • EUR 494.00
  • EUR 161.00
  • 500uG
  • 100uG
Description: Minimum order quantity: 1 unit of 100uG

Alpha-bungarotoxin, CF633

9-00009
  • EUR 494.00
  • EUR 161.00
  • 500uG
  • 100uG
Description: Minimum order quantity: 1 unit of 500uG

Alpha-bungarotoxin, CF633

9-00009
  • EUR 494.00
  • EUR 161.00
  • 500uG
  • 100uG
Description: Minimum order quantity: 1 unit of 100uG

Alpha-bungarotoxin

00010-1 1MG
EUR 168
Description: Minimum order quantity: 1 unit of 1MG

Fluorescein-Alpha-bungarotoxin

00011 500uG
EUR 367
Description: Minimum order quantity: 1 unit of 500uG

Tetramethylrhodamine-Alpha-bungarotoxin

00012 500uG
EUR 383
Description: Minimum order quantity: 1 unit of 500uG

Fluorescein-alpha-bungarotoxin: (10x50ug)

00013 10ST
EUR 417
Description: Minimum order quantity: 1 unit of 10ST